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IX. Malignant Melanoma and Vitiligo 
The brown pigment that gives human skin its distinctive hue 
is a protein material, melanin. Melanin is manufactw-ed within 
specialized skin cells called melanocytes. An enzyme, tyrosinase, 
converts the soluble amino acid tyrosine to the insoluble pig-
ment melanin in a series of reactions within the pigment cells. 
This melanin is packaged in the form of small granules called 
melanosomes. During the pigmentation process melanosomes 
are transferred from the pigment cells to adjacent epidermal 
cells. 
Various skin colors are the result of different amounts of 
melanin within the epidermal cells. Racial variations of skin 
coloring correlate with the amount of melanin produced and 
transferred. In all races, the number of pigment cells is approx-
imately the same. DW'ing the tanning process, sunlight causes 
an increase in pigment production within the melanocytes. 
Subsequently, increased nwnbers of melanin granules are trans-
ferred to the skin cells and result in the ·darkening of the skin 
color. 
Total skin color can be thought of as consisting of two 
components: (1) constitutional skin color, which is the base 
amount of melanin produced and transferred according to the 
genetic make-up of an individual, and (2) facultative skin color, 
which is the amount of color generated under the influence of 
acquired factors, such as sunlight, hormones, illness, etc. Fac-
ultative skin color added to constitutive skin color gives the 
total skin color. Because the continual production and regular 
transfer of pigment is necessary to maintain normal constitutive 
skin color, defects at any stage of the pigmentation process may 
lead to pigment disorders. 
A wide range of disorders of the pigment system has been 
described. There are inherited defects of melanin production, 
such as albinism; there are inflammatory diseases that increase 
pigment production, such as postinflammatory hyperpigmen-
tation; there are hormonal problems that affect melanin for-
mation, such as Addison's disease; there are disorders in which 
pigment cells are selectively destroyed by toxins, such as ger-
micide (phenolic) hypopigmentation; and there are dis'eases 
characterized by the proliferation of pigment cells, such as nevi, 
lentigines, and malignant melanoma. 
Two disorders have been selected from this wide range of 
problems to be discussed in detail: melanoma and vitiligo. 
These diseases have been selected because of their high fre-
quency and serious consequences. 
1. MELANOMA 
Melanoma is a cancer of the pigment producing cells of the 
skin, eyes, and mucous membranes. Untreated, this disease 
usually spreads widely within the body and is fatal. Melanoma 
may develop from a mole that becomes malignant or it may 
arise from pigment cells in normal appearing skin. The recog-
nition of melanoma dw-ing its early stages is fateful because a 
patient may be cured if the tumor is eradicated completely 
before the cells have spread throughout the body. 
Prevalence and Severity 
Melanoma, a relatively common form of cancer, constitutes 
1% of the cancers in the United States. The American Cancer 
Society estimates that 9,500 new cases of melanoma appear 
each year in this country, a figure equal to that for cancer of 
the larynx and exceeding that of brain tumors. The age adjusted 
annual incidence is 4.2 per 100,000 population. 
Since 1960, a rapid incl'ease in the incidence and mortality 
rates for melanoma has been noted. In California, the age-
adjusted mortality rate for melanoma doubled from 1945 to 
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1971. Nationwide, the incidence of melanomas has the second 
fastest growth rate of any cancer, exceeded only by tumors of 
the lung. Although more complete recognition and registration 
of melanomas certainly have contributed to the increasing rates, 
the actual increase in the true incidence is unexplained. Perhaps 
gradual changes in the manner of living of many Americans, 
thei.r greater exposw-e to sunlight, account for at least part of 
this change. Approximately 3,000 people die from melanoma in 
the United States each year. 
Estimates of annual cost: Because the tumor often affects 
young people in their productive years, melanoma is propor-
tionately more costly than other malignancies. The financial 
bw-den of melanoma treatment programs which include surgical 
procedures, hospital care, and the cost of caring for terminally 
ill patients, amounts to millions of dollars per year. The psy-
chological burden is especially heavy for melanoma patients 
and their families because of the uncertainty of treatment 
effectiveness. Because the course of melanoma is so erratic, 
patients who have sw-vived 5 years or longer without evidence 
of metastatic spread may still die from this disease at a later 
time. 
Prevention, Treatment, and Cure 
The cause of melanoma, like that of other cancers, is un-
known. Exposure to ultraviolet light may contribute to the 
development of melanoma. The greater use of sunscreens, 
therefore, may possibly lead to a decrease in the susceptibility 
to melanoma. Except for surgical excision, there is no regularly 
successful treatment for melanoma, especially for those tumors ' 
that have spread throughout the body. 
Although the general clinical features of melanoma are well 
known, certain details in the natural history of the disorder are 
obscure. These details are now being studied in large groups of 
melanoma patients at Harvard, New York University, Temple 
University, and the University of California. This Melanoma 
Clinical Co-operative Group study has been in operation since 
September 1972, and has recorded more than 1,200 cases of 
primary melanoma in its fIles along with color photographs, 
histologic sections, and medical data. The completed study 
should provide insights into .factors that influence the disease 
and characteristics of individuals who are especially susceptible 
to melanoma. 
As indicated above, an important feature of melanoma is the 
possibility of cure if identified in the early stages. Education is 
now directed toward both physicians and the public to promote 
earlier recognition of melanoma. Because the tumor appears 
flJ'st on the skin, early diagnosis is a realizable goal. It has been 
estimated that if early recognition becomes a reality, the 5-year 
survival of this disease may increase from 50% to 85%. 
Status of Research 
The primary goal of many researchers in this field has been 
to understand the basic biological principles underlying the 
transformation of normal pigment cells into melanoma cells. 
Work in this field has been concerned with the influence of 
viral, toxic, chemical, immunologic, and genetic factors and is 
being pursued vigorously in many centers. One significant re-
cent advance is the identification of a special familial type of 
melanoma. The widespread clinical recognition of heightened 
susceptibility to this disease in certain families should lead to 
earlier recognition and earlier, more effective treatment. 
Another advance in the field of melanoma is the finding of a 
correlation of the depth of the primary tumor, as measured 
histologically, with the patient's prognosis. Such information 
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obtained from excised tissue is also helpful in the selection of 
appropriate therapy. For example, patients whose lesions have 
shown minimal invasion generally receive less aggressive ther-
apy and still can be assured of an adequate prognosis. On the 
other hand, those patients with deeper involvement generally 
receive more aggressive forms of therapy designed to decrease 
the risk of recurrence. 
Viral particles may be related to the production of the tumor. 
Work is proceeding to define this presumed virus/cancer rela-
tionship more precisely. Research into specific forms of therapy 
is also active. 
Because the melanocyte has so many distinctive biologic 
features, effort is now being directed toward the use of these 
characteristics to develop a therapeutic program that would 
destroy only melanoma cells. One feature of the pigment cell is 
its ability to bind to certain hormones. Attempts are under way 
to attach cytotoxic agents to the hormones. In this way toxic 
agents could be delivered selectively and in high concentration 
to the pigment cells. Chemical agents that are selectively toxic 
to pigment cells have been identified, and attempts are being 
made to use these compounds to destroy melanoma cells selec-
tively. 
Immunologic principles are also being applied to develop new 
treatments. Several observations have pointed to the presence 
of a protective immune reaction against melanomas in most 
individuals: the spontaneous regression of established melano-
mas, the loss of pigment in areas of tumor regression (which 
has been interpreted as a vigorous but local antimelanocyte 
reaction by the body), and the prolonged disease-free intervals 
between the' time of tumor excision and the appearance of 
metastases. This last finding suggests that certain host factors 
are able to confme the tumor to local sites for long periods. 
Therefore, methods for stimulating the immune system so that 
tumor growth can be slowed are now being sought. 
One particularly attractive approach has been through the 
identification of antigens unique to melanoma celis. These 
"tumor" antigens, which may be recognized by the body as 
foreign, may stimulate both humoral and cellular immune 
responses. Such antibodies, directed against melanoma celis, 
already have been identified in patients with this cance.r. The 
antibodies are cytotoxic and can specifically destroy melanoma 
cells in cell culture, yet do no harm to unrelated cells. Attempts 
are now under way to boost the immune response in patients 
with melanoma in order to strengthen this autoimmune reac-
tion. The remarkable ability of the body's immune system to 
recognize different types of cells permits selective destruction 
of melanoma cells without damage to other tissues. 
Needs for Addition.al Basic Research 
Of high priority is the continued support of basic research to 
discover how normal skin pigment cells (melanocytes) are trans-
formed into malignant melanoma cells. For this purpose we 
need nOl-mal melanocytes in culture. An animal model that 
closely mimics the natural history of melanoma in man is 
needed. Research shOUld to be concerned with the influence of 
viral, chemical, immunologic, and genetic factors on melanocyte 
transformation. 
Viral particles have been detected in human melanoma cells 
from human beings. These particles have some properties in 
common with RNA tumor viruses. Work is needed to define 
this relationship more precisely. 
Studies are now underway to bind cytotoxic agents to hor-
mones and to direct t hese hormones specifically to melanoma 
cells. Such studies deserve continued support as possibly lead-
ing to chemotherapeutic agents for patients with melanomas. 
Studies on the application of immunologic principles to the 
treatment of malignant melanoma deserve considerable sup-
port. We need to find tumor antigens and learn how the immune 
system can be stimulated to slow tumor growth. 
While tumor antigens induce immune responses that increase 
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the host resistance to tumor formation, they also interfere with 
the immune destruction of cancer cells. Ways must be found to 
maximize the host resistance and minimize the melanoma cell 
resistance. Success in this area could lead to treatments in 
which patients with histories of melanomas could have their 
immune response (i.e., the production of cytotoxic antibodies) 
stimulated to increase their resistance against tumor formation 
without incurring the risk of increasing the resistance of pre-
existing melanoma cells. 
Research should be supported on genetic factors that m ay 
heighten the susceptibili ty of some people to melanomas. The 
outcome of such research would lead to earlier recognition and 
treatment. 
Needs for Additional Clinical Research 
Studies on the efficacy of surgical excision of melanomas are 
timely. There are suggestions that wide excisions and amputa_ 
tion are unnecessary. The value of lymph node dissection is in. 
question. The proper combination of surgery and chemotherapy 
must be established. There is a high positive correlation of the 
depth of the primary tumor and the patient's prognosis, and 
studies on this finding deserve continued support in order to 
develop better prognostic indicators. 
Sunlight appears to be influential in the production of mela_ 
nomas. Extensive epidemiological studies would define the re-
lationship of melanomas to exposure to sunlight and to othet 
environmental agents. 
2. VITILIGO 
Vitiligo is a common disorder of the pigment system of the 
skin in which the pigment cells of the epidermis disappear 
thereby causing the skin to turn white. Most commonly, th~ 
disease leaves large white patches around the eyes, nose, mouth, 
nipples, genitalia, and hands. In persons with light-colored skin, 
the disease may not be apparent. For most darker-skinned 
individuals, however, or those with widespread areas of depig_ 
mentation, especially on exposed portions of the body, the 
cosmetic effects can be devastating. A few patients may lose all 
the pigment within their skin; that is, their pigmented skin 
turns starkly white . 
Usually the white spots are first noted by the patient on the 
exposed areas of the skin or in the body folds, often during the 
summer months after a tan has been acquired. Examination 
reveals depigmentation most often on the face, back, hands, 
and wrists. In fair-skinned individuals, patches of depigmenta-
tion can be seen more easily under a special ultraviolet lamp 
that heightens the contrast between the light and dark areas. 
Sites of trauma or recent injury usually become white, and at 
times the border between the white patches and the normally 
colored skin becomes inflamed or hyperpigmented. Careful 
observation usually reveals many shades of color in a single 
patient. The disorder begins before age 20 in approximately 
one-half of patients. 
Pre valance and Severity 
One million Americans have vitiligo, about 0.5% of the pop-
ulation. Its prevalence among the older age groups approaches 
I%". 
A recent study has shown that among patients who think 
that they have "significant" skin pathology, those with vitiligo 
are more likely to be "concerned;" that is, it bothers them more 
than those with most other dermatologic problems. Thus, al-
though vitiligo is not a lethal disease or even especially symp-
tomatic,.its effects may be devastating. Sociologists have found 
that vitiligo has a major impact on patients' self-esteem. Over 
one-half of the patients with vitiligo say that the disease has 
significantly interfered with their ability to interact with others 
socially. Patients have been denied jobs because of vitiligo. 
Even friends and spouses are prone to reject the patients in 
subtle ways. 
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Estimates of annual cost: Vitiligo is a disease for which the 
American people and the medical profession have had little 
sYJIlpathy or interest. It is difficult at the present time to assess 
the financial burden. It is of greater importance to remember 
that the debilitat ing consequences of such a nonfatal disease 
may have a disastrous impact on the quality of an individual's 
life whether or not his physical health is impaired. 
Prevention, Treatment, and Cure 
Drugs, usually administered with UV light, are available for 
the treatment of vitiligo. Although they may improve the 
appearance of the patient somewhat, they rarely induce total 
repigmentation of all the white spots. Repigmenting therapy 
often takes several years and requires an enormous expenditure 
of time by the patient and large doses of encouragement by the 
physician. Because of the disappointing results of this form of 
therapy, patients often are rebuffed or advised to ignore the 
white patches or to cover them with cosmetics; this is usually 
unsu ccessfuJ. 
Status of Research Activities 
The cause of vitiligo is unknown. At one time it was thought 
that vitiligo was a defect in melanin synthesis within the pig-
men t cells of the epidermis. Now it is clear that the defect is 
not one of pigment production; rather the pigment cells them-
selves are lost or destroyed. Two hypotheses have been ad-
vance d to explain pigment cell loss. First, a selective destruction 
of the pigment cells results from the effects of a locally active 
toxic material. Two sources for this toxin are postulated: one 
postulate holds that the pigment cells themselves produce the 
toxin during the normal melanization process (metabolites of 
the tyrosine pathway have been shown experimentally to cause 
pigment cell death), the other holds that the neurosecretory 
apparatus of the skin produces the toxin (vitiligo occasionally 
follows a nerve-pattern distribution). Second, the destruction 
of the melanocytes in vitiligo implicates an autoimmune process 
in which antibodies, produced by the immune system, become 
directed against autologous pigment cells. Although there is 
little direct evidence to support the autoimmune hypothesis, it 
is being studied vigorously. It is known that vitiligo is associated 
with other immune disorders, such as thyroiditis, pernicious 
anemia, etc., and that in patients with the unusual constellation 
of diabetes, pernicious anemia, candidiasis, and alopecia areata, 
vitiligo also develops. Certain specific serum factors in these 
patients are fixed to the pigment cells, suggesting an immuno-
logically mediated response. A recent modification of the im-
mune h ypothesis has been proposed: people who have immu-
nologic defects may have circulating cells that are strongly 
sensitized to antigens related to those of pigment cells. If 
additional factors that suppress the activity of these circulating 
antimelanocyte cells are destroyed, pigment cell loss may pro-
ceed . 
Microscopic changes have been observed at the border of the 
white patches. It has been noted that the melanocytes in the 
border zone of active vitiligo are biologically different in some 
subtle way from other melanocytes. A careful analysis of the 
light and electron-microscopic changes in vitiligo is under way 
in an attempt to correlate these changes with the clinical stages 
of the disease and to gain an understanding of how the mela-
nocytes are destroyed. 
Other studies are directed at the social impact of the disease 
and its epidemiology. A fruitful area of recent study has been 
the relationship of the eyes to vitiligo. The eyes contain several 
varieties of pigment cells that are known to be critical for 
normal vision. A disease that destroys the pigment cells of the 
skin might be expected to affect similar cells of the eyes. 
Recently, it has been shown that over half of the patients with 
vitiligo have abnormalities of the pigment system of their eyes 
and a few patients have serious visual disturbances. Although 
most c omplain only of mild to moderate photophobia, it is 
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possible t hat many patients are legally blind owing to the 
destruction of visual pigment related to vitiligo. 
A final area of study concerns the relationship of vitiligo to 
melanoma. Although vitiligo affects less than 1% of the general 
population, it is intriguing that 20-30% of patients who have 
melanoma also have vitiligo. Why should such biologically 
opposite activities, that is, both uncontrolled proliferation and 
destruction of pigment cells, occur in the same patient? It has 
been suggested that an immune reaction that is directed at the 
melanoma also kills benign pigment cells. Many workers now 
believe t hat proper application of basic knowledge about vitiligo 
may be the key to a specific therapy for this especially malig-
nant form of cancer . 
Needs for Additional Basic Research 
It is important to understand the basic mechanisms under-
lying the loss of melanocytes. We must find ways to treat 
patients with vitiligo. 
Studies need to be supported to determine whether the 
autogenic destruction of pigment cells is in response to the 
formation of a locally-active toxic material (either formed in 
the pigment cells themselves or in the neurosecretory apparatus 
of the skin), is the result of an autoimmune process in which 
antibodies are directed against one's own pigment cells, or is 
related to some combination of the two processes. 
Needs for Additional Clinical Research 
The relationship of vitiligo to abnormalities in the pigment 
system of the eye deserves study. A few patients with vitiligo 
have reported serious disturbance, and many complain of de-
creased night vision. 
The nature of the relationship of vitiligo to melanoma must 
be established. Preliminary studies indicate that patients with 
both melanoma and vitiligo survive longer than those who do . 
not have vitiligo. Can the mechanisms of vitiligo be identified 
and, if so, can they be translated into a treatment method for 
modifying or, better yet, curing malignant melanoma? 
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